No black box warning on record for Zynlonta

As of the latest FDA labeling reviewed, Zynlonta (LONCASTUXIMAB TESIRINE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Zynlonta medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Effusion and Edema, Including Capillary Leak Syndrome : Monitor for the development of pleural effusion, pericardial effusion, ascites, peripheral edema, and general edema. Consider diagnostic imaging when symptoms develop or worsen. ( 5.1 ) Myelosuppression: Monitor blood cell counts. Withhold, reduce, or discontinue ZYNLONTA based on severity. ( 5.2 ) Infections : Moni

No black box warning on record for Zynlonta

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Effusion and Edema, Including Capillary Leak Syndrome : Monitor for the development of pleural effusion, pericardial effusion, ascites, peripheral edema, and general edema. Consider diagnostic imaging when symptoms develop or worsen. ( 5.1 ) Myelosuppression: Monitor blood cell counts. Withhold, reduce, or discontinue ZYNLONTA based on severity. ( 5.2 ) Infections : Moni

Zynlonta Black Box Warning

No black box warning on record for Zynlonta

Other warnings & precautions

Zynlonta Black Box Warning

No black box warning on record for Zynlonta

Other warnings & precautions